Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

A U.S. appeals court on Friday revived a whistleblower lawsuit accusing Swiss drugmaker Novartis of paying illegal kickbacks ...

Second Circuit Partially Affirms Novartis’ Motion to Dismiss AKS Claims - Last week, the Second Circuit Court of Appeals affirmed ...

More than three years after Novartis’ plan for a speedy approval for intrathecal Zolgensma was thwarted by an FDA requirement ...

Novartis AG said a new experimental medicine improved motor function in children with a form of spinal muscular atrophy, the ...

Novartis (NYSE:NVS) said a Phase 3 study of an intrathecal formulation of its gene therapy Zolgensma, also known as OAV101 IT ...

SAN DIEGO--(BUSINESS WIRE)--Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, announced a multi-target collaboration with Novartis to identify and develop ...

First Hawaiian Bank lessened its position in Novartis AG (NYSE:NVS – Free Report) by 2.8% during the 4th quarter, according ...

Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully ...

Novartis’ Zolgensma, an IV formulation, was FDA-approved in 2019 for patients under two with SMA. However, the new IT ...